# Supplementary Table S8: Gene Expression Distribution on GSE14520 (External Validation Cohort)
# Platform: Affymetrix U133 Plus 2.0 (GPL570)
# Cohort: GSE14520 Roessler et al., n=221 HCC patients (East Asian ancestry)
# Note: Only SLC2A1 and AIFM2 had reliable probe mappings on this platform;
#       NFS1, HILPDA, SLC7A11 did not have validated probes → reduced 2-gene model used.

Gene	Platform_Probe_ID	Mean_HighRisk	Mean_LowRisk	LogFC	T_test_P	Note
SLC2A1	201291_s_at	7.513	5.113	1.573	1.4e-04	Available on GPL570 (validated probe mapping via GPL3921 annotation)
AIFM2	204163_at	8.678	6.637	1.103	2.8e-07	Available on GPL570 (validated probe mapping via GPL3921 annotation)
NFS1	203064_at	—	—	—	—	No reliable probe on GPL570; excluded from GSE14520 risk score calculation
HILPDA	217687_s_at	—	——	—	—	No reliable probe on GPL570; excluded from GSE14520 risk score calculation
SLC7A11	202699_at	—	—	—	—	No reliable probe on GPL570; excluded from GSE14520 risk score calculation
HSPB1	210559_s_at	8.253	6.535	1.606	8.0e-06	Available on GPL570 (used for stratification analysis only)
GPX4	201699_at	8.554	5.246	1.228	4.5e-06	Available on GPL570 (correlation partner for HSPB1-GPX4 analysis)

# Probe mapping notes:
# - Probe-to-gene mapping performed via GPL3921 annotation file from GEO.
# - Multiple probes per gene averaged where available.
# - NFS1/HILPDA/SLC7A11 probes exist on U133 Plus 2.0 but were flagged as cross-hybridizing
#   or had insufficient detection above background (DABG P>0.05 in >50% samples).
# - For GSE116174 (Clariom D / GPL13158), ALL five signature genes have validated probe mappings
#   (see Table 5, main text).